[Jeon Hwasung's Startup Morning Coffee #1084] Fundraising, The Path to Success

## Startup Morning Coffee Spotlights 'Tyroh,' Opening New Horizons in Intractable Cancer Treatment CEO Jeon Hwa-sung's 'Startup Morning Coffee,' broadcast live every morning at 8:40 AM on the YouTube channel 'Jeon Hwa-sung's CNTV,' has established itself as a leading communication platform that invigorates the startup ecosystem. The program deeply illuminates the core competencies and market potential of promising companies, providing useful information through interactive communication with viewers via real-time comments. Recently, bio-startup Tyroh, which is opening new horizons in intractable cancer treatment, was introduced here, drawing significant attention. **Innovative Bio Company 'Tyroh' Transcends Cancer Treatment Limitations with Targeted Radiopharmaceutical Complexes** Tyroh is a bio-company that aims to overcome the limitations of existing anticancer treatments and provide patients with innovative cancer treatment solutions that are more effective and have fewer side effects. In particular, by utilizing meticulously designed radiopharmaceutical complexes, it focuses on developing anticancer substances that specifically target cancer cells, thereby offering new hope to suffering patients. Currently, Tyroh is rapidly growing and advancing its technological capabilities through CNT Tech's sports accelerating support program. **Tyroh's Core Competency: 'Meticulous Targeting Technology' Protecting Normal Cells** Tyroh's unique core competitiveness lies in its 'meticulous radiopharmaceutical complex design and synthesis technology'. This goes beyond merely using radioactive isotopes; it is an intelligent method that minimizes damage to surrounding normal cells by inducing them to selectively bind only to cancer cells. Tyroh, by continuously dedicating itself to developing complex structures that maximize in-vivo stability and efficient cancer cell delivery, has the potential to dramatically reduce the chronic side effects of conventional radiation therapy or chemotherapy and exponentially increase treatment success rates. This precise targeting technology is evaluated as a crucial key that can fundamentally change the paradigm of cancer treatment. **CEO Jeon Hwa-sung's Perspective: 'Tyroh' to Change the Future of the Global Anticancer Drug Market** Regarding Tyroh's technology, CEO Jeon Hwa-sung highly praised it, stating that it "possesses innovative technology and unique market potential in the field of intractable cancer treatment." He particularly emphasized that, coupled with the explosive growth of the targeted radiopharmaceutical market, Tyroh's unique radiopharmaceutical complex development capability will be a core driving force to fundamentally change the paradigm of cancer treatment. In the future, through continuous clinical research and pipeline expansion, Tyroh is expected to establish itself as a true leader in the global anticancer drug market.